G1 Therapeutics (NASDAQ:GTHX) insider Mark A. Velleca sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $36.00, for a total transaction of $270,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of GTHX opened at $40.68 on Wednesday. G1 Therapeutics has a 1 year low of $12.04 and a 1 year high of $42.78.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). equities analysts expect that G1 Therapeutics will post -2.47 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new stake in G1 Therapeutics during the 3rd quarter valued at approximately $568,000. Franklin Resources Inc. grew its holdings in G1 Therapeutics by 10.1% during the 4th quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock valued at $30,467,000 after buying an additional 141,000 shares in the last quarter. Swiss National Bank purchased a new stake in G1 Therapeutics during the 4th quarter valued at approximately $286,000. Virtus Fund Advisers LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at approximately $350,000. Finally, Ellington Management Group LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at approximately $294,000. 42.10% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have commented on GTHX shares. BTIG Research started coverage on shares of G1 Therapeutics in a research note on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price on the stock. BidaskClub upgraded shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. JPMorgan Chase increased their price objective on shares of G1 Therapeutics to $30.00 in a report on Monday, February 5th. Zacks Investment Research lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Monday, March 5th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $38.20.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Macon Daily and is the property of of Macon Daily. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://macondaily.com/2018/04/18/g1-therapeutics-gthx-insider-mark-a-velleca-sells-7500-shares.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.